Advances and future directions in the treatment of hepatocellular carcinoma

Ashil J. Gosalia, Paul Martin, Patricia D. Jones

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths worldwide. Liver transplant is considered the gold standard for curative therapy for HCC when patients are not candidates for surgical resection or ablation. Because a subset of patients with HCC have a survival rate with liver transplantation that is comparable to that of cirrhotic patients without tumors, the organ allocation system allows for increased priority for transplant in potential recipients within the Milan criteria. With the recent change in the Model for End-Stage Liver Disease exception point allocation, patients with HCC will now need to wait at least 6 months before being awarded extra points. This extension leads to increased time on the transplant waiting list and underscores the importance of locoregional therapy to contain the tumor burden. Fortunately, there has been significant progress in therapy for HCC in the past few decades, namely due to advances in interventional radiology, radiotherapy, and expanded surgical and transplant criteria. Recent advances in immunotherapy also provide promising options for patients who are not candidates for other therapies. This article highlights the major therapeutic options for HCC, including surgical resection, liver transplant, thermal and nonthermal ablation, chemoembolization, radiotherapy, and systemic chemotherapy, as well as discusses the evidence supporting these approaches.

Original languageEnglish (US)
Pages (from-to)398-410
Number of pages13
JournalGastroenterology and Hepatology
Volume13
Issue number7
StatePublished - Jul 1 2017

Fingerprint

Hepatocellular Carcinoma
Transplants
Radiotherapy
Therapeutics
Interventional Radiology
End Stage Liver Disease
Waiting Lists
Liver
Tumor Burden
Liver Transplantation
Immunotherapy
Direction compound
Neoplasms
Survival Rate
Hot Temperature
Drug Therapy

Keywords

  • Hepatocellular carcinoma
  • Immunotherapy
  • Interventional oncology
  • Treatment

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Advances and future directions in the treatment of hepatocellular carcinoma. / Gosalia, Ashil J.; Martin, Paul; Jones, Patricia D.

In: Gastroenterology and Hepatology, Vol. 13, No. 7, 01.07.2017, p. 398-410.

Research output: Contribution to journalArticle

Gosalia, Ashil J. ; Martin, Paul ; Jones, Patricia D. / Advances and future directions in the treatment of hepatocellular carcinoma. In: Gastroenterology and Hepatology. 2017 ; Vol. 13, No. 7. pp. 398-410.
@article{f2a4a7cb3c8c4416b60ce07dfb15f4c9,
title = "Advances and future directions in the treatment of hepatocellular carcinoma",
abstract = "Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths worldwide. Liver transplant is considered the gold standard for curative therapy for HCC when patients are not candidates for surgical resection or ablation. Because a subset of patients with HCC have a survival rate with liver transplantation that is comparable to that of cirrhotic patients without tumors, the organ allocation system allows for increased priority for transplant in potential recipients within the Milan criteria. With the recent change in the Model for End-Stage Liver Disease exception point allocation, patients with HCC will now need to wait at least 6 months before being awarded extra points. This extension leads to increased time on the transplant waiting list and underscores the importance of locoregional therapy to contain the tumor burden. Fortunately, there has been significant progress in therapy for HCC in the past few decades, namely due to advances in interventional radiology, radiotherapy, and expanded surgical and transplant criteria. Recent advances in immunotherapy also provide promising options for patients who are not candidates for other therapies. This article highlights the major therapeutic options for HCC, including surgical resection, liver transplant, thermal and nonthermal ablation, chemoembolization, radiotherapy, and systemic chemotherapy, as well as discusses the evidence supporting these approaches.",
keywords = "Hepatocellular carcinoma, Immunotherapy, Interventional oncology, Treatment",
author = "Gosalia, {Ashil J.} and Paul Martin and Jones, {Patricia D.}",
year = "2017",
month = "7",
day = "1",
language = "English (US)",
volume = "13",
pages = "398--410",
journal = "Gastroenterology and Hepatology",
issn = "1554-7914",
publisher = "Gastro-Hep Communications, Inc.",
number = "7",

}

TY - JOUR

T1 - Advances and future directions in the treatment of hepatocellular carcinoma

AU - Gosalia, Ashil J.

AU - Martin, Paul

AU - Jones, Patricia D.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths worldwide. Liver transplant is considered the gold standard for curative therapy for HCC when patients are not candidates for surgical resection or ablation. Because a subset of patients with HCC have a survival rate with liver transplantation that is comparable to that of cirrhotic patients without tumors, the organ allocation system allows for increased priority for transplant in potential recipients within the Milan criteria. With the recent change in the Model for End-Stage Liver Disease exception point allocation, patients with HCC will now need to wait at least 6 months before being awarded extra points. This extension leads to increased time on the transplant waiting list and underscores the importance of locoregional therapy to contain the tumor burden. Fortunately, there has been significant progress in therapy for HCC in the past few decades, namely due to advances in interventional radiology, radiotherapy, and expanded surgical and transplant criteria. Recent advances in immunotherapy also provide promising options for patients who are not candidates for other therapies. This article highlights the major therapeutic options for HCC, including surgical resection, liver transplant, thermal and nonthermal ablation, chemoembolization, radiotherapy, and systemic chemotherapy, as well as discusses the evidence supporting these approaches.

AB - Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths worldwide. Liver transplant is considered the gold standard for curative therapy for HCC when patients are not candidates for surgical resection or ablation. Because a subset of patients with HCC have a survival rate with liver transplantation that is comparable to that of cirrhotic patients without tumors, the organ allocation system allows for increased priority for transplant in potential recipients within the Milan criteria. With the recent change in the Model for End-Stage Liver Disease exception point allocation, patients with HCC will now need to wait at least 6 months before being awarded extra points. This extension leads to increased time on the transplant waiting list and underscores the importance of locoregional therapy to contain the tumor burden. Fortunately, there has been significant progress in therapy for HCC in the past few decades, namely due to advances in interventional radiology, radiotherapy, and expanded surgical and transplant criteria. Recent advances in immunotherapy also provide promising options for patients who are not candidates for other therapies. This article highlights the major therapeutic options for HCC, including surgical resection, liver transplant, thermal and nonthermal ablation, chemoembolization, radiotherapy, and systemic chemotherapy, as well as discusses the evidence supporting these approaches.

KW - Hepatocellular carcinoma

KW - Immunotherapy

KW - Interventional oncology

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85026653093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026653093&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85026653093

VL - 13

SP - 398

EP - 410

JO - Gastroenterology and Hepatology

JF - Gastroenterology and Hepatology

SN - 1554-7914

IS - 7

ER -